Henan Taloph Pharmaceutical Stock Co Ltd Strategic Asset Allocation Index

Latest as of September 2022: 33.5%

Henan Taloph Pharmaceutical Stock Co Ltd strategic asset allocation index. Henan Taloph Pharmaceutical Stock Co Ltd (600222) has a Strategic Asset Allocation Index of 33.5% as of September 2022. Strategic assets (PP&E of CN¥538.86 Million plus long-term investments of CN¥-) total CN¥538.86 Million, measured against net assets of CN¥1.61 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Henan Taloph Pharmaceutical Stock Co Ltd (600222) net asset quality to measure how much of total assets are equity-financed.

SAAI

33.5%
Strategic Assets / Net Assets

Strategic Assets

CN¥538.86 Million
PP&E + LT Investments

PP&E

CN¥538.86 Million
CNY

Net Assets

CN¥1.61 Billion
CNY

Strategic Asset Allocation Index of Henan Taloph Pharmaceutical Stock Co Ltd (2000–2021)

Strategic asset allocation index of Henan Taloph Pharmaceutical Stock Co Ltd from 2000 to 2021. This chart shows how Henan Taloph Pharmaceutical Stock Co Ltd's Strategic Asset Allocation Index has evolved across 22 annual periods from 2000 to 2021. As of September 2022, the index stands at 33.5%, representing strategic assets of CN¥538.86 Million against net assets of CN¥1.61 Billion CNY. Check Henan Taloph Pharmaceutical Stock Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Henan Taloph Pharmaceutical Stock Co Ltd Strategic Asset Allocation Index by Year (2000–2021)

Henan Taloph Pharmaceutical Stock Co Ltd strategic asset allocation index by year from 2000 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Henan Taloph Pharmaceutical Stock Co Ltd from 2000 to 2021, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Henan Taloph Pharmaceutical Stock Co Ltd stock valuation.

Year SAAI Strategic Assets (CNY) PP&E LT Investments Net Assets Change (pp)
2021 30.4% CN¥539.58 Million CN¥539.58 Million CN¥- CN¥1.78 Billion ▼ -1.9 pp
2020 32.3% CN¥494.09 Million CN¥494.09 Million CN¥- CN¥1.53 Billion ▼ -1.9 pp
2019 34.2% CN¥448.82 Million CN¥448.82 Million CN¥- CN¥1.31 Billion ▼ -10.5 pp
2018 44.7% CN¥621.73 Million CN¥481.96 Million CN¥139.77 Million CN¥1.39 Billion ▼ -4.0 pp
2017 48.7% CN¥734.76 Million CN¥614.71 Million CN¥120.05 Million CN¥1.51 Billion ▼ -6.6 pp
2016 55.4% CN¥830.43 Million CN¥710.25 Million CN¥120.18 Million CN¥1.50 Billion ▲ +2.6 pp
2015 52.8% CN¥791.63 Million CN¥715.95 Million CN¥75.68 Million CN¥1.50 Billion ▼ -3.2 pp
2014 56.0% CN¥664.55 Million CN¥664.55 Million CN¥- CN¥1.19 Billion ▼ -6.9 pp
2013 62.9% CN¥687.64 Million CN¥687.64 Million CN¥- CN¥1.09 Billion ▼ -44.8 pp
2012 107.8% CN¥707.60 Million CN¥707.60 Million CN¥- CN¥656.50 Million ▼ -4.2 pp
2011 111.9% CN¥704.04 Million CN¥704.04 Million CN¥- CN¥628.89 Million ▲ +12.5 pp
2010 99.5% CN¥606.24 Million CN¥606.24 Million CN¥- CN¥609.32 Million ▲ +3.9 pp
2009 95.6% CN¥560.45 Million CN¥560.45 Million CN¥- CN¥586.04 Million ▲ +5.0 pp
2008 90.6% CN¥502.89 Million CN¥502.89 Million CN¥- CN¥554.97 Million ▲ +9.1 pp
2007 81.5% CN¥425.32 Million CN¥425.32 Million CN¥- CN¥521.57 Million ▲ +6.5 pp
2006 75.0% CN¥365.48 Million CN¥365.48 Million CN¥- CN¥487.05 Million ▲ +1.9 pp
2005 73.1% CN¥345.00 Million CN¥345.00 Million CN¥- CN¥471.96 Million ▲ +7.5 pp
2004 65.6% CN¥298.76 Million CN¥298.76 Million CN¥- CN¥455.68 Million ▲ +2.4 pp
2003 63.1% CN¥278.12 Million CN¥278.12 Million CN¥- CN¥440.61 Million ▼ -1.5 pp
2002 64.6% CN¥276.69 Million CN¥276.69 Million CN¥- CN¥428.30 Million ▼ -1.8 pp
2001 66.4% CN¥276.73 Million CN¥276.73 Million CN¥- CN¥416.84 Million ▲ +10.9 pp
2000 55.5% CN¥227.63 Million CN¥227.63 Million CN¥- CN¥410.41 Million —
pp = percentage points